Maxcyte (MXCT) Accumulated Expenses (2020 - 2026)

Maxcyte (MXCT) has 7 years of Accumulated Expenses data on file, last reported at $4.4 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 13.15% year-over-year to $4.4 million in Q1 2026; TTM through Mar 2026 was $4.4 million, a 13.15% decrease from a year earlier, with the FY2025 full-year figure at $7.8 million, down 5.9% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $4.4 million, down from $7.8 million in the prior quarter.
• Over the last five years, Accumulated Expenses for MXCT reached as high as $11.3 million in Q4 2023 and fell as low as $3.9 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $7.3 million across 5 years, with a median of $7.8 million in 2025.
• Across the five-year window, Accumulated Expenses surged 78.59% in 2023 and fell 26.33% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $8.3 million in 2022, then jumped by 36.35% to $11.3 million in 2023, then decreased by 26.33% to $8.3 million in 2024, then slipped by 5.9% to $7.8 million in 2025, then plunged by 44.05% to $4.4 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $4.4 million in Q1 2026, $7.8 million in Q4 2025, and $8.3 million in Q3 2025.